Neo Ivy Capital Management Acquires Shares of 8,718 The Cooper Companies, Inc. (NASDAQ:COO)

Neo Ivy Capital Management bought a new position in The Cooper Companies, Inc. (NASDAQ:COO - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 8,718 shares of the medical device company's stock, valued at approximately $962,000.

Other institutional investors and hedge funds have also modified their holdings of the company. LRI Investments LLC grew its stake in Cooper Companies by 4.5% during the 2nd quarter. LRI Investments LLC now owns 2,595 shares of the medical device company's stock valued at $227,000 after acquiring an additional 112 shares in the last quarter. Mitchell & Pahl Private Wealth LLC lifted its position in Cooper Companies by 1.5% in the 3rd quarter. Mitchell & Pahl Private Wealth LLC now owns 7,986 shares of the medical device company's stock worth $881,000 after buying an additional 117 shares in the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of Cooper Companies by 0.8% during the 2nd quarter. Commonwealth Equity Services LLC now owns 15,600 shares of the medical device company's stock valued at $1,362,000 after buying an additional 118 shares during the period. Bleakley Financial Group LLC grew its holdings in shares of Cooper Companies by 2.1% during the 3rd quarter. Bleakley Financial Group LLC now owns 5,767 shares of the medical device company's stock valued at $636,000 after acquiring an additional 119 shares in the last quarter. Finally, First Horizon Advisors Inc. increased its stake in shares of Cooper Companies by 4.8% in the second quarter. First Horizon Advisors Inc. now owns 2,709 shares of the medical device company's stock worth $236,000 after acquiring an additional 125 shares during the last quarter. Hedge funds and other institutional investors own 24.39% of the company's stock.

Insider Buying and Selling at Cooper Companies

In other news, CEO Albert G. White III sold 114,992 shares of Cooper Companies stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the sale, the chief executive officer now owns 165,273 shares of the company's stock, valued at approximately $18,267,624.69. This trade represents a 41.03 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.00% of the company's stock.

Cooper Companies Stock Performance

Shares of Cooper Companies stock traded down $2.56 during trading on Thursday, reaching $96.72. The company's stock had a trading volume of 1,731,882 shares, compared to its average volume of 1,161,198. The Cooper Companies, Inc. has a one year low of $84.76 and a one year high of $112.38. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. The firm has a market cap of $19.26 billion, a price-to-earnings ratio of 49.60, a price-to-earnings-growth ratio of 2.17 and a beta of 0.97. The business's fifty day moving average price is $103.71 and its 200-day moving average price is $98.87.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its quarterly earnings results on Thursday, December 5th. The medical device company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.00 by $0.04. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.03 billion. During the same period in the previous year, the business posted $0.87 EPS. The company's revenue for the quarter was up 9.8% on a year-over-year basis. As a group, equities research analysts predict that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have commented on the company. Piper Sandler boosted their target price on Cooper Companies from $115.00 to $120.00 and gave the company an "overweight" rating in a research note on Thursday, August 29th. Needham & Company LLC reissued a "hold" rating on shares of Cooper Companies in a research note on Friday, December 6th. Citigroup reduced their target price on shares of Cooper Companies from $116.00 to $115.00 and set a "buy" rating for the company in a research note on Friday, December 6th. Stifel Nicolaus restated a "buy" rating and set a $115.00 price target (up previously from $110.00) on shares of Cooper Companies in a research note on Thursday, August 29th. Finally, Morgan Stanley cut their price target on shares of Cooper Companies from $104.00 to $102.00 and set an "equal weight" rating on the stock in a report on Friday, December 6th. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $117.00.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.